OpGen

OpGen Operating Cash Flow

The Operating Cash Flow of OpGen (OPGN) as of Oct 19, 2026 is -1.18 M USD. In the previous year, Operating Cash Flow was -4.87 M USD — a change of -75.69% (higher).

Operating Cash Flow

-1.18 MUSD

YoY

-75.69%

Last updated:

Operating Cash Flow of OpGen is 2025 -1.18 M USD. Operating Cash Flow of OpGen was 2024 -4.87 M USD. It decreases by -75.69% higher compared to the previous year.

The OpGen Operating Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Operating Cash Flow
Date
Operating Cash Flow
Jan 1, 2018
-11.07 M USD
Jan 1, 2019
-11.51 M USD
Jan 1, 2020
-23.40 M USD
Jan 1, 2021
-21.48 M USD
Jan 1, 2022
-20.45 M USD
Jan 1, 2023
-14.32 M USD
Jan 1, 2024
-4.87 M USD
Jan 1, 2025
-1.18 M USD
The OpGen Operating Cash Flow history
YEAROperating Cash FlowYoY
-1.18 MUSD-75.69%
-4.87 MUSD-65.99%
-14.32 MUSD-29.98%
-20.45 MUSD-4.79%
-21.48 MUSD-8.19%
-23.40 MUSD+103.35%
-11.51 MUSD+3.90%
-11.07 MUSD-22.58%
-14.30 MUSD-17.08%
-17.25 MUSD+20.82%
-14.28 MUSD+165.12%
-5.39 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

OpGen Stock analysis

What does OpGen do? OpGen Inc is a biotechnology company based in Gaithersburg, Maryland, operating within the Health Care sector. The company went public on May 5, 2015, with ticker OPGN and ISIN US68373L5057. It currently employs three people. OpGen develops molecular information solutions focused on combating infectious diseases in global healthcare settings. The company's technology involves DNA tests and bioinformatics to address antibiotic resistance, assisting healthcare providers in managing patient care decisions and monitoring the spread of multidrug-resistant microorganisms. Its solutions aim to guide clinicians with information about life-threatening infections and help manage patient outcomes. The company's website is http://opgen.com/. OpGen is engaged in creating tools to help protect the hospital biome through customized screening and surveillance. The firm markets its high-resolution DNA tests under the Acuitas trade name. The company has a global network of customers and partners. OpGen does not provide specific details on its product names beyond Acuitas, and no additional financial figures or historical data are available in the provided information. OpGen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about OpGen stock

Operating Cash Flow of OpGen is -1.18 M USD in 2025.

Operating Cash Flow of OpGen changed from -4.87 M USD to -1.18 M USD, representing a -75.69% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow OpGen since 2006 – with annual values, charts, and detailed analysis.

Operating cash flow measures the cash generated from core business operations. It is a pure measure of a company's ability to generate cash.

Operating Cash Flow's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Operating Cash Flow's OpGen historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — OpGen

All Key Metrics — OpGen